Oncolytics Biotech Inc. sold 1,532,278 common shares at $5.83 apiece for gross proceeds of about $8.9 million in a public offering.
The shares sold included 160,065 common shares issued as part of the underwriters' overallotment option.
Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for the offering.
Alberta, Canada-based Oncolytics Biotech is a development stage biopharmaceutical company, which focuses on the discovery and development of pharmaceutical products to treat cancer.
